2023-02-24-世界卫生组织-6._Influenza_B_Yamagata_Lineage_-_Cell_culture-derived_-_Northern_Hemisphere_2023-2024_2页_181kb

报告摘要

The recommended vaccine strains for the 2023-2024 northern hemisphere influenza season include B-type viruses of the Yamagata lineage.
Cell-derived Candidate Vaccine Viruses (ccCVVs):
- Viruses were isolated using WHO-approved cell lines (e.g., MDCK 33016 PFa, NIID-MDCKb).
- These ccCVVs have undergone two-way hemagglutination inhibition (HI) testing against matching WHO prototype strains but no other testing (e.g., for adventitious agents) has been conducted by WHO Centers.
Recombinant Vaccine Antigen(s):
- Sequence closely matches B/Phuket/3073/2013, possibly derived from MDCK-SIAT cell lines.

B/Phuket/3073/2013 (Accession number: EPI_ISL_161843):
- Used as the reference strain.
- Isolated using MDCK 33016 PF at WHO Collaborating Centre, VIDRL (Australia).
- Passages noted for this derivation.
- Available Passages: P2.
Other B-lineage viruses listed (e.g., B/Singapore/INFTT-16-0610/2016) served as parent viruses or for genetic analysis; details vary.

Reference Antigens:
- B(y)-Ag-2001 (lot 44, CBER/FDA, USA - equivalent to B/Phuket/3073/2013).
- Other lots (e.g., B(y)-Ag-1501, 19/308, 19/322) associated with different B lineages/viruses.
Wild Type Viruses: Involves B/Utah/9/2014, B/Singapore/INFTT-16-0610/2016 (wild type derived from specific cell lines/institutes).

National/regional control authorities approve vaccine composition/formulation.
Vaccines may be derived from egg or cell (here, cell-derived ccCVVs).
Updates and orders can be directed via WHO links provided or contacting specific Essential Regulatory Laboratories (ERLs) or WHO Collaborating Centres like CBER/FDA, MHRA, NIID, TGA.